New antiretroviral may help failing PI regimens.
Researchers at the first International AIDS Society Conference presented findings that demonstrated the potency of a new type of antiretroviral medication: the non-peptidic protease inhibitor (NPPI). We present a Q&A with Martin Markowitz, MD, an investigator with the Aaron Diamond AIDS Research Center in New York City, about this new class of drug and about research he and others have been conducting on the first NPPI drug to have Phase II data.
Markowitz
M
M
Aaron Diamond AIDS Research Center, New York City, USA.
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008561:Membrane Fusion / Q000187:drug effects; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011753:Pyrones / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir